登记Id

PA130232992

药物名称(英)

bevacizumab

通用名称

Avastin,R-435,antiVEGF,bevacizumab

商品名称

Avastin

品牌组合

类型(英)

Drug

类型

药品

交叉引用

"Canadian Drugs Product Database:02270994","Chemical Abstracts Service:216974-75-3","ClinicalTrials.gov:NCT00088894","ClinicalTrials.gov:NCT00110214","ClinicalTrials.gov:NCT00467142","ClinicalTrials.gov:NCT00537173","ClinicalTrials.gov:NCT00621686","ClinicalTrials.gov:NCT00798603","ClinicalTrials.gov:NCT00826540","ClinicalTrials.gov:NCT01217398","ClinicalTrials.gov:NCT01338753","ClinicalTrials.gov:NCT01359397","ClinicalTrials.gov:NCT01426880","ClinicalTrials.gov:NCT01745757","ClinicalTrials.gov:NCT01814163","ClinicalTrials.gov:NCT01831089","ClinicalTrials.gov:NCT01935102","ClinicalTrials.gov:NCT01959490","DrugBank:DB00112","FDA Drug Label at DailyMed:939b5d1f-9fb2-4499-80ef-0607aa6b114e","National Drug Code Directory:50242-060-01","Therapeutic Targets Database:DAP000393","URL:http://en.wikipedia.org/wiki/Bevacizumab"

简化分子线性输入规范

键

剂量指南

No

外部词汇

"ATC:L01XC07(bevacizumab)","UMLS:C0796392(bevacizumab)","RxNorm:253337(bevacizumab)","NDFRT:N0000148845(BEVACIZUMAB)"

RxNorm 标识符

253337

ATC 标识符

L01XC07

化合物标识符